fluoxetine has been researched along with Gelineau Syndrome in 7 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The majority of recent papers in this field provide information about use of modafinil or sodium oxybate for treatment of sleepiness associated with narcolepsy." | 4.84 | Treatment of narcolepsy and other hypersomnias of central origin. ( Arand, DL; Auger, RR; Brooks, SN; Watson, NF; Wise, MS, 2007) |
| "Successful treatment of hypersomnia of central origin requires an accurate diagnosis, individual tailoring of therapy to produce the fullest possible return of normal function, and regular follow-up to monitor response to treatment." | 2.44 | Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. ( Alessi, C; Aurora, RN; Boehlecke, B; Brown, T; Chesson, AL; Friedman, L; Kapur, VK; Maganti, R; Morgenthaler, TI; Owens, J; Pancer, J; Swick, TJ; Zak, R, 2007) |
| "Saudi patients with narcolepsy have the same clinical presentation as reported in the Western literature." | 1.33 | Narcolepsy in Saudi Arabia. Demographic and clinical perspective of an under-recognized disorder. ( Alenezi, AM; BaHammam, AS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soltanifar, S | 1 |
| Russell, R | 1 |
| Wisor, JP | 1 |
| Eriksson, KS | 1 |
| Poryazova, R | 1 |
| Siccoli, M | 1 |
| Werth, E | 1 |
| Bassetti, CL | 1 |
| BaHammam, AS | 1 |
| Alenezi, AM | 1 |
| Morgenthaler, TI | 1 |
| Kapur, VK | 1 |
| Brown, T | 1 |
| Swick, TJ | 1 |
| Alessi, C | 1 |
| Aurora, RN | 1 |
| Boehlecke, B | 1 |
| Chesson, AL | 1 |
| Friedman, L | 1 |
| Maganti, R | 1 |
| Owens, J | 1 |
| Pancer, J | 1 |
| Zak, R | 1 |
| Wise, MS | 1 |
| Arand, DL | 1 |
| Auger, RR | 1 |
| Brooks, SN | 1 |
| Watson, NF | 1 |
| Wing, YK | 1 |
| Lee, S | 1 |
| Chiu, HF | 1 |
| Ho, CK | 1 |
| Chen, CN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Caffeine on the Narcoleptic Patients Randomized Controlled Clinical Trial[NCT02832336] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2016-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluoxetine and Gelineau Syndrome
| Article | Year |
|---|---|
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
Treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
5 other studies available for fluoxetine and Gelineau Syndrome
| Article | Year |
|---|---|
Neuraxial anaesthesia for caesarean section in a patient with narcolepsy and cataplexy.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antidepressive Agents, Second-Generation; Benz | 2010 |
Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil.
Topics: Adrenergic Agents; Animals; Benzhydryl Compounds; Benzylamines; Brain; Central Nervous System Stimul | 2005 |
Unusually prolonged rebound cataplexy after withdrawal of fluoxetine.
Topics: Brain Stem; Cataplexy; Electroencephalography; Electromyography; Female; Fluoxetine; Humans; Middle | 2005 |
Narcolepsy in Saudi Arabia. Demographic and clinical perspective of an under-recognized disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Ant | 2006 |
A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine.
Topics: Accidents, Traffic; Adult; Craniocerebral Trauma; Fluoxetine; Humans; Jealousy; Male; Narcolepsy; Pa | 1994 |